Biznes i finanse

Raport bieżący 30/2017

Raport bieżący 15/2017

Raport bieżący 30/2017

Raport bieżący 29/2017

Raport bieżący 41/2017

Raport bieżący z plikiem 15/2017

<ul>
<li>The 8-year follow-up results of a randomized phase 3 multicenter trial in adult patients with hematologic malignancies clearly showed more favorable results in the Grafalon® group;</li>
</ul>
<ul>
<li>Severe GvHD-free and relapse-free survival was 34% in the Grafalon® group versus 13% in non-Grafalon® group;</li>
</ul>
<ul>
<li>The probability of being alive and free of immunosuppressive therapy was 47% in Grafalon® group versus 11% in non-Grafalon® group;</li>
</ul>
<ul>
<li>Relapse mortality was not increased by Grafalon®, supporting the long-term safety of Grafalon®.</li>
</ul>

Raport bieżący z plikiem 12/2017

Raport bieżący 45/2017